MedTrace Logo

Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

NCT01714648 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-08-04

No results posted yet for this study

Summary

Ovarian hyperstimulation syndrome (OHSS) is a major complication of ovarian stimulation for IVF if hCG is used to trigger final oocyte maturation. The investigators propose that using GnRH agonist as a trigger will eliminate OHSS, even in high-risk patients.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Triptorelin 0.2 mg

A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.

Sponsors & Collaborators

Principal Investigators

  • Shahar Kol, MD · Elisha Hospital, Haifa, Israel

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01714648 on ClinicalTrials.gov